Singular Genomics Systems, Inc. Common Stock
OMIC
OMIC was delisted on the 20th of February, 2025.
62 hedge funds and large institutions have $450M invested in Singular Genomics Systems, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 8 reducing their positions, and 10 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 8
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
44% more capital invested
Capital invested by funds: $312M → $450M (+$138M)
19% more funds holding
Funds holding: 52 → 62 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.7M |
| 2 |
JP Morgan Chase
New York
|
+$8.24M |
| 3 |
BlackRock
New York
|
+$6.34M |
| 4 |
PA
Perceptive Advisors
New York
|
+$3.36M |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$16.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$5.23M |
| 3 |
Millennium Management
New York
|
-$5.08M |
| 4 |
JPC
Jabodon PT Co
Reno,
Nevada
|
-$1.11M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$891K |
OMIC Hedge Fund Activity: Q4 2021 in Review
62 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q4 2021, worth a combined $450M — up 44% from $312M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new OMIC positions and 10 closed out — a net gain of 10 holders — while 24 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $16.7M. The largest seller was Casdin Capital, cutting an estimated $16.2M.
- 62 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q4 2021, up from 52 in Q3 2021.
- Funds reported $450M of Singular Genomics Systems, Inc. Common Stock stock for Q4 2021, up 44% quarter-over-quarter.
- 20 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q4 2021 and 10 closed out, a net change of +10 holders.
- The largest Singular Genomics Systems, Inc. Common Stock buyer in Q4 2021 was Vanguard Group, an estimated $16.7M added.
- The largest Singular Genomics Systems, Inc. Common Stock seller in Q4 2021 was Casdin Capital, an estimated $16.2M sold.
Based on aggregated 13F filings for Q4 2021.